# CJC-1295 / About — Editorial method, entity, and the disclaimer in plain language > CJC-1295 Order is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic, do not sell any product, and are not affiliated with any vendor. What this site is, what it is not, and why the 'order' modifier is editorial framing rather than a service claim. ## What this site is CJC-1295 / Order is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. The site is structured as a navigable network of findings — twenty research nodes connected by directed edges that route from mechanism through Phase 1 pharmacokinetics through the terminated Phase 2 program through detection methodology through the regulatory mesh. The network-topology framing is the editorial argument: the compound's story is connected, not linear, and the reader navigates by following relationships between findings rather than by reading a long-form essay. The primary research record on CJC-1295 is small. Two Phase 1 trials, one halted Phase 2 program, a half-dozen analytical-chemistry papers, and a handful of preclinical models. That body of evidence is tractable, but the secondary literature around it routinely misrepresents what was actually administered, conflates the with-DAC and no-DAC variants, or invents dosing protocols that no trial ever tested. An editorial summary that reads the primary papers, cites them correctly, and indexes the findings against their original DOIs is useful as a reference point. ## What this site is not CJC-1295 / Order is not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute CJC-1295 or any other compound. We do not accept orders. We do not maintain any fulfillment infrastructure, payment processing, or supply relationship. We are not affiliated with any vendor, pharmacy, telehealth provider, manufacturer, distributor, or research-chemical supplier. We do not refer readers to any vendor, pharmacy, telehealth provider, manufacturer, distributor, or research-chemical supplier. The 'order' modifier in the domain name cjc1295order.com is editorial framing — the position of structured acquisition that the publisher occupies relative to the literature, not a claim about services offered. CJC-1295's defining pharmacokinetic feature is that it joins the body's circulatory mesh via covalent albumin conjugation rather than passing through it as a free peptide. The Network Flow aesthetic that organizes this site is a structural reading of that fact: nodes, edges, hubs, and a directed graph of trial-program and regulatory relationships. 'Order' is the structural register, not a transaction. ## Editorial method Every page on this site is editorial commentary on publicly available science. Source material is the primary peer-reviewed literature indexed on PubMed and PMC, plus the ClinicalTrials.gov registry entry for NCT00267527 (the terminated Phase 2 program) and the WADA Prohibited List. Every quantitative claim — dose value, half-life range, study count, percentage change — cites a specific primary source by DOI or PubMed/PMC URL. The /references page lists all sources used. We do not cite forum posts, anonymous blog content, vendor marketing pages, or secondary lifestyle-medicine summaries as sources for factual claims. Where the published record is silent or incomplete, the page says so. Where a study was halted before publication of its endpoints (NCT00267527), the page documents the halt and notes the absence of peer-reviewed outcome data. Where a mechanistic concern (such as IGF-1-mediated mitogenic risk) exists in adjacent literature but has not been directly studied for CJC-1295, the page documents the concern and notes the empirical gap [17]. ## Disclaimer, in plain language CJC-1295 is not approved for human use by FDA, EMA, MHRA, TGA, PMDA, or any other regulatory authority for any indication. The compound is listed by name under Section S2 (subsection 2.3) of the World Anti-Doping Agency Prohibited List and is prohibited at all times for athletes under WADA jurisdiction. Nothing on this site constitutes medical advice, a dosing recommendation, or an invitation to use, acquire, or distribute the compound. The doses reported on /dosage are the doses administered to research subjects in named published studies — they are reported as research-context, not as protocols for any reader. This site is an independent editorial digest of publicly available science. It is not a clinic. It is not affiliated with any vendor, pharmacy, telehealth provider, manufacturer, or distributor. The footer on every page is the editorial contract. --- An editorial summary of peer-reviewed findings — not a clinical recommendation, not a vendor, not a node in any supply graph.